Developing Effective Alzheimer’s Disease Therapies: Clinical Experience and Future Directions
Tóm tắt
Từ khóa
Tài liệu tham khảo
Farlow, 2002, A clinical overview of cholinesterase inhibitors in Alzheimer’s disease, Int Psychogeriatr, 14, 93, 10.1017/S1041610203008688
Cummings, 2014, Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures, Alzheimers Res Ther, 6, 37, 10.1186/alzrt269
Dubois, 2015, Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer’s disease, Alzheimers Dement, 11, 1041, 10.1016/j.jalz.2014.10.003
Molinuevo, 2005, Memantine: Targeting glutamate excitotoxicity in Alzheimer’s disease and other dementias, Am J Alzheimers Dis Other Demen, 20, 77, 10.1177/153331750502000206
Tanzi, 2005, Twenty years of the Alzheimer’s disease amyloid hypothesis: A genetic perspective, Cell, 120, 545, 10.1016/j.cell.2005.02.008
Bertram, 2010, The genetics of Alzheimer disease: Back to the future, Neuron, 68, 270, 10.1016/j.neuron.2010.10.013
Tanzi, 2012, The genetics of Alzheimer disease, Cold Spring Harb Perspect Med, 2, a006296, 10.1101/cshperspect.a006296
Tanzi, 2013, A brief history of Alzheimer’s disease gene discovery, J Alzheimers Dis, 33, S5
Bertram, 2008, Genome-wide association analysis reveals putative Alzheimer’s disease susceptibility loci in addition to APOE, Am J Hum Genet, 83, 623, 10.1016/j.ajhg.2008.10.008
Guerreiro, 2013, TREM2 variants in Alzheimer’s disease, N Engl J Med, 368, 117, 10.1056/NEJMoa1211851
Jonsson, 2013, Variant of TREM2 associated with the risk of Alzheimer’s disease, N Engl J Med, 368, 107, 10.1056/NEJMoa1211103
Akter, 2011, Diabetes mellitus and Alzheimer’s disease: Shared pathology and treatment?, Br J Clin Pharmacol, 71, 365, 10.1111/j.1365-2125.2010.03830.x
Sando, 2008, Risk-reducing effect of education in Alzheimer’s disease, Int J Geriatr Psychiatry, 23, 1156, 10.1002/gps.2043
Selkoe, 2001, Alzheimer’s disease results from the cerebral accumulation and cytotoxicity of amyloid β -protein, J Alzheimers Dis, 3, 75, 10.3233/JAD-2001-3111
Townsend, 2006, Effects of secreted oligomers of amyloid β -protein on hippocampal synaptic plasticity: A potent role for trimers, J Physio, 572, 477, 10.1113/jphysiol.2005.103754
Cardenas-Aguayo, 2014, Neurochemistry
Luo, 1996, Physiological levels of beta-amyloid peptide promote PC12 cell proliferation, Neurosci Lett, 217, 125, 10.1016/0304-3940(96)13087-1
Moya, 1994, The amyloid precursor protein is developmentally regulated and correlated with synaptogenesis, Dev Biol, 1612, 597, 10.1006/dbio.1994.1055
Mileusnic, 2000, APP is required during an early phase of memory formation, Eur J Neurosci, 12, 4487, 10.1046/j.1460-9568.2000.01344.x
Selkoe, 2001, Alzheimer’s disease: Genes, proteins, and therapy, Physiol Rev, 81, 741, 10.1152/physrev.2001.81.2.741
Hardy, 2002, The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics, Science, 297, 353, 10.1126/science.1072994
Jansen, 2015, Prevalence of cerebral amyloid pathology in persons without dementia: A meta-analysis, JAMA, 313, 1924, 10.1001/jama.2015.4668
Jack, 2013, Biomarker modeling of Alzheimer’s disease, Neuron, 80, 1347, 10.1016/j.neuron.2013.12.003
Albert, 2011, The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease, Alzheimers Dement, 7, 270, 10.1016/j.jalz.2011.03.008
Iqbal, 2009, Mechanisms of tau-induced neurodegeneration, Acta Neuropathol, 118, 53, 10.1007/s00401-009-0486-3
Choi, 2014, A three-dimensional human neural cell culture model of Alzheimer’s disease, Nature, 515, 274, 10.1038/nature13800
Bilousova, 2016, Synaptic amyloid-beta oligomers precede p-tau and differentiate high pathology control cases, Am J Pathol, 186, 185, 10.1016/j.ajpath.2015.09.018
Johnson, 2016, Tau positron emission tomographic imaging in aging and early Alzheimer disease, Ann Neurol, 79, 110, 10.1002/ana.24546
Braak, 1997, Frequency of stages of Alzheimer-related lesions in different age categories, Neurobiol Aging, 18, 351, 10.1016/S0197-4580(97)00056-0
Schneider, 2008, Tau-based treatment strategies in neurodegenerative diseases, Neurotherapeutics, 5, 443, 10.1016/j.nurt.2008.05.006
Šimić, 2016, Tau protein hyperphosphorylation and aggregation in Alzheimer’s disease and other tauopathies, and possible neuroprotective strategies, Biomolecules, 6, 6, 10.3390/biom6010006
Ow, 2014, A brief overview of amyloids and Alzheimer’s disease, Protein Sci, 23, 1315, 10.1002/pro.2524
Lee, 2012, Tau and tauopathies, Prog Mol Biol Transl Sci, 107, 263, 10.1016/B978-0-12-385883-2.00004-7
Hong, 2016, Complement and microglia mediate early synapse loss in Alzheimer mouse models, Science, 352, 712, 10.1126/science.aad8373
Griciuc, 2013, Alzheimer’s disease risk gene CD33 inhibits microglial uptake of amyloid beta, Neuron, 78, 631, 10.1016/j.neuron.2013.04.014
Park, 2018, A 3D human triculture system modeling neurodegeneration and neuroinflammation in Alzheimer’s disease, Nat Neurosci, 21, 941, 10.1038/s41593-018-0175-4
Wilcock, 2012, A changing perspective on the role of neuroinflammation in Alzheimer’s disease, Int J Alzheimers Dis, 2012, 495243
McGeer, 2015, Targeting microglia for the treatment of Alzheimer’s disease, Expert Opin Ther Targets, 19, 497, 10.1517/14728222.2014.988707
Asai, 2015, Depletion of microglia and inhibition of exosome synthesis halt tau propagation, Nat Neurosci, 18, 1584, 10.1038/nn.4132
Katsel, 2009, Gain in brain immunity in the oldest-old differentiates cognitively normal from demented individuals, PLoS One, 4, e7642, 10.1371/journal.pone.0007642
Burstein, 2018, Development of azeliragon, an oral small molecule antagonist of the receptor for advanced glycation endproducts, for the potential slowing of loss of cognition in mild Alzheimer’s disease, J Prev Alzheimers Dis, 5, 149
Soininen, 2007, Long-term efficacy and safety of celecoxib in Alzheimer’s disease, Dement Geriatr Cogn Disord, 23, 8, 10.1159/000096588
Butchart, 2015, Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, Phase 2 trial, Neurology, 84, 2161, 10.1212/WNL.0000000000001617
Wan, 2009, Translational medicine lessons from flurizan’s failure in Alzheimer’s disease (AD) trial: Implication for future drug discovery and development for AD, Clin Transl Sci, 2, 242, 10.1111/j.1752-8062.2009.00121.x
Potter, 2017, Interim report of Phase 2 pilot safety and efficacy trial of GM-CSF/Leukine in mild-to-moderate Alzheimer’s disease, Alzheimers Dement, 13, P1572, 10.1016/j.jalz.2017.07.735
Relkin, 2017, A Phase 3 trial of IV immunoglobulin for Alzheimer disease, Neurology, 88, 1, 10.1212/WNL.0000000000003904
Aisen, 2000, A randomized controlled trial of prednisone in Alzheimer’s disease. Alzheimer’s Disease Cooperative Study, Neurology, 54, 588, 10.1212/WNL.54.3.588
Aisen, 2003, Effects of rofecoxib or naproxen vs placebo on Alzheimer’s disease progression: A randomized controlled trial, JAMA, 289, 2819, 10.1001/jama.289.21.2819
Kile, 2017, IVIG treatment of mild cognitive impairment due to Alzheimer’s disease: A randomised double-blinded exploratory study of the effect on brain atrophy, cognition and conversion to dementia, J Neurol Neurosurg Psychiatry, 88, 106, 10.1136/jnnp-2015-311486
Decourt, 2017, Poor safety and tolerability hamper reaching a potentially therapeutic dose in the use of thalidomide for Alzheimer’s disease: Results from a double-blind, placebo-controlled trial, Curr Alzheimer Res, 14, 403, 10.2174/1567205014666170117141330
McGeer, 1996, Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer’s disease: A review of 17 epidemiologic studies, Neurology, 47, 425, 10.1212/WNL.47.2.425
in ‘t Veld, 1998, NSAIDs and incident Alzheimer’s disease. The Rotterdam Study, Neurobiol Aging, 19, 607, 10.1016/S0197-4580(98)00096-7
Pasqualetti, 2009, A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer’s disease, Aging Clin Exp Res, 21, 102, 10.1007/BF03325217
Galimberti, 2011, Disease-modifying treatments for Alzheimer’s disease, Ther Adv Neurol Disord, 4, 203, 10.1177/1756285611404470
Mangialasche, 2010, Alzheimer’s disease: Clinical trials and drug development, Lancet Neurol, 9, 702, 10.1016/S1474-4422(10)70119-8
Huang, 2017, A common haplotype lowers PU.1 expression in myeloid cells and delays onset of Alzheimer’s disease, Nat Neurosci, 20, 1052, 10.1038/nn.4587
Hung, 2017, Drug candidates in clinical trials for Alzheimer’s disease, J Biomed Sci, 24, 47, 10.1186/s12929-017-0355-7
Vassar, 2014, BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease, Alzheimers Res Ther, 6, 89, 10.1186/s13195-014-0089-7
Atri, 2018, Effect of idalopirdine as adjunct to cholinesterase inhibitors on change in cognition in patients with Alzheimer disease: Three randomized clinical trials, JAMA, 319, 130, 10.1001/jama.2017.20373
Fullerton, 2018, A Phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer’s disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil, Alzheimers Res Ther, 10, 38, 10.1186/s13195-018-0368-9
Haig, 2014, A randomized study of H3 antagonist ABT-288 in mild-to-moderate Alzheimer’s dementia, J Alzheimers Dis, 42, 959, 10.3233/JAD-140291
Grove, 2014, A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer’s disease, Curr Alzheimer Res, 11, 47, 10.2174/1567205010666131212110148
Mohs, 2009, Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study, Am J Geriatr Psychiatry, 17, 752, 10.1097/JGP.0b013e3181aad585
Cano-Cuenca, 2014, Evidence for the efficacy of latrepirdine (dimebon) treatment for improvement of cognitive function: A meta-analysis, J Alzheimers Dis, 38, 155, 10.3233/JAD-130872
Nave, 2017, Sembragiline in moderate Alzheimer’s disease: Results of a randomized, double-blind, placebo-controlled phase II trial (MAyflOwer RoAD), J Alzheimers Dis, 58, 1217, 10.3233/JAD-161309
Vellas, 2011, EHT0202 in Alzheimer’s disease: A 3-month, randomized, placebo-controlled, double-blind study, Curr Alzheimer Res, 8, 203, 10.2174/156720511795256053
Coric, 2012, Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease, Arch Neurol, 3, 1
Green, 2009, Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: A randomized controlled trial, JAMA, 302, 2557, 10.1001/jama.2009.1866
Doody, 2013, A Phase 3 trial of semagacestat for treatment of Alzheimer’s disease, N Engl J Med, 369, 341, 10.1056/NEJMoa1210951
Vandenberghe, 2016, Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, Phase 3 trials, Alzheimers Res Ther, 8, 18, 10.1186/s13195-016-0189-7
Ostrowitzki, 2017, A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease, Alzheimers Res Ther, 9, 95, 10.1186/s13195-017-0318-y
Gauthier, 2016, Phase 3 trial of the tau aggregation inhibitor leuco-methylthionium-bis (hydropethanesulfonate) (LMTM) in mild to moderate Alzheimer’s disease, Alzheimers Dement, 12, P351, 10.1016/j.jalz.2016.06.650
Zhang, 2018, Cromolyn reduces levels of the Alzheimer’s disease-associated amyloid β-protein by promoting microglial phagocytosis, Sci Rep, 8, 1
Hori, 2015, A Food and Drug Administration-approved asthma therapeutic agent impacts amyloid beta in the brain in a transgenic model of Alzheimer disease, J Biol Chem, 290, 1966, 10.1074/jbc.M114.586602
Cummings, 2018, Lessons learned from Alzheimer disease: Clinical trials with negative outcomes, Clin Transl Sci, 11, 147, 10.1111/cts.12491
Gamberger, 2017, Identification of clusters of rapid and slow decliners among subjects at risk for Alzheimer’s disease, Sci Rep, 7, 1, 10.1038/s41598-017-06624-y
Becker, 2008, Why do so many drugs for Alzheimer’s disease fail in development? Time for new methods and new practices?, J Alzheimers Dis, 15, 303, 10.3233/JAD-2008-15213
Aisen, 2015, Cognitive/clinical endpoints for pre-dementia AD trials, J Prev Alzheimers Dis, 2, 82
Doody, 2009, Donepezil treatment of patients with MCI: A 48-week randomized, placebo-controlled trial, Neurology, 72, 1555, 10.1212/01.wnl.0000344650.95823.03
Williams, 2013, Progression of Alzheimer’s disease as measured by Clinical Dementia Rating Sum of Boxes scores, Alzheimers Dement, 9, S39, 10.1016/j.jalz.2012.01.005
Delnomdedieu, 2016, First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer’s disease, Alzheimers Res Ther, 8, 12, 10.1186/s13195-016-0177-y
Nicoll, 2003, Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: A case report, Nat Med, 9, 448, 10.1038/nm840
Galasko, 2014, A randomized clinical trial of an inhibitor of RAGE-Aβ interactions in patients with mild to moderate AD, Neurology, 82, 1536, 10.1212/WNL.0000000000000364
Cummings, 2016, Double-blind, placebo-controlled, proof-of-concept trial of bexarotene X in moderate Alzheimer’s disease, Alzheimers Res Ther, 8, 4, 10.1186/s13195-016-0173-2
Salloway, 2009, A Phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease, Neurology, 73, 2061, 10.1212/WNL.0b013e3181c67808
Heneka, 2015, Neuroinflammation in Alzheimer’s disease, Lancet Neurol, 14, 388, 10.1016/S1474-4422(15)70016-5
Niemantsverdriet, 2017, Alzheimer’s disease CSF biomarkers: Clinical indications and rational use, Acta Neurol Belg, 117, 591, 10.1007/s13760-017-0816-5
McKhann, 2011, The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease, Alzheimers Dement, 7, 263, 10.1016/j.jalz.2011.03.005
Burchell, 2017, New cerebrospinal fluid biomarkers in Alzheimer’s disease, Future Neurol, 12, 53, 10.2217/fnl-2017-0009
Pontecorvo, 2017, Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition, Brain, 140, 748